These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter.
    Author: Ou YC, Gardner TA, Kao C, Zhau HE, Chung LW.
    Journal: Anticancer Res; 2005; 25(2A):881-6. PubMed ID: 15868923.
    Abstract:
    BACKGROUND: The expression of the MN/carbonic anhydrase IX (CA IX) protein is detected in renal cell carcinoma (RCC). A tumor-specific MN promoter was designed and evaluated. MATERIALS AND METHODS: Western blot, reverse transcription-PCR and Northern blot for MN expression were performed on Hela cells, LNCaP and four human RCC cell lines. The MN promoter (554 bp) was cloned into pGL3 luciferase reporter vectors and their activities were tested. RESULTS: Hela cells, SKRC-31 and SKRC-38 expressed high levels of MN RNA and MN protein. The MN promoter has 5- to 10-fold higher activity in MN-positive cell lines than in MN-negative cell lines. It could enhance the activity of the basic SV40 early promoter (6 to 25 fold) in MN-positive cells but not in MN-negative cells. CONCLUSION: MN expression in RCC may derive from altered expression of transcriptional factor(s), which binds to the MN enhancer element, and can be used for tumor specific toxic gene therapy for RCC.
    [Abstract] [Full Text] [Related] [New Search]